About akronbiotech

Akron Biotech is an leading biotechnology company focused on discovery, development and manufacturing of advanced tools for regenerative medicine.

Court denies University of California appeal, upholding the Broad Institute patents on CRISPR gene editing

The US Court of Appeals for the Federal Circuit upheld a previous decision by the US Patent and Trademark Office which awarded the intellectual property on CRISPR-Cas9 gene editing technology to the Broad Institute of the Massachusetts Institute of Technology and Harvard University, striking down an appeal by University of California, Berkeley and the University

Immunotherapy crosses blood-brain barrier to target glioblastoma

Chimeric antigen receptor T cell (CAR T) therapies have proved remarkably effective against leukemia and lymphoma, but for these therapies to target other types of cancer, there are still hurdles to overcome. Brain cancer is particularly challenging for immunotherapies due to the blood-brain barrier. This semi-permeable barrier tightly regulates the homeostasis of the central nervous

Upcoming Events – September 2018

As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes.  Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility

Elephants’ resistance to cancer may provide new inspiration for drug development

If all cells have a similar risk of mutation and equivalent cancer suppression mechanisms, then large organisms with many cells should have a higher risk of developing cancer than small organisms with fewer cells. However, there is no correlation between body size and cancer risk across species, a phenomenon often called “Peto’s paradox”. Elephants are

Macrophages derived from stem cells help mice to breathe again

Hereditary pulmonary alveolar proteinosis (herPAP) is a rare life-threatening disease characterized by the slow accumulation of lipoproteins in the lungs. Surfactant and other lipoproteins are typically cleared from alveoli by a specialized group of cells called alveolar macrophages that require the signaling molecule termed granulocyte macrophage colony-stimulating growth factor (GM-CSF) to maintain normal surfactant levels.

Engineered lungs successfully transplanted into pigs

A daunting challenge that faces tissue engineering is the requirement to generate perfused microvasculature networks capable of delivering nutrients to and removing waste from tissues. This engineered circulatory system is critical to supporting tissue survival. Vascularization is particularly important for the production of bioengineered lungs, which requires coordination of the circulatory and respiratory systems to

Akron co-sponsors the 11th annual Business of Regenerative Medicine Symposium at the University of Pennsylvania

The 11th annual Business of Regenerative Medicine: Innovation, Clinical Translation, and Entrepreneurship Symposium took place on July 17th-18th. The event was hosted by the Center for Cellular Immunotherapies and the Institute for Regenerative Medicine at the University of Pennsylvania in partnership with Case Western Reserve University, the Harvard Stem Cell Institute, the Parker H. Petit

Nanoparticle-bound TLR agonists re-educate tumor supportive M2 macrophages

Tumor supportive M2-type macrophages generally prevail over their tumoricidal M1 counterparts in the tumor environment. It follows that efforts have been undertaken to either deplete M2-like cells or convert the macrophage phenotype into M1-like cells. M1- and M2-like polarization states differ in cell morphology and this divergence can be leveraged to individuate drugs that efficiently